GDX 015
Alternative Names: GDX-015Latest Information Update: 28 May 2025
At a glance
- Originator GammaDelta Therapeutics
- Developer Takeda
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom (Parenteral)
- 26 Apr 2021 Preclinical trials in Solid tumours in United Kingdom (Parenteral) (GammaDelta Therapeutics pipeline, April 2021)
- 05 Jun 2018 GammaDelta Therapeutics acquires Lymphact